Non-Infectious Macular Edema Treatment Market 2027 By Drug Type, Route of Administration, Distribution Channel | The Insight Partners

Non-Infectious Macular Edema Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Type (Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics, Others); Route of Administration (Oral, Topical, Others); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)

Report Code: TIPRE00016867 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Macular edema is highly observed sight-threatening condition in uveitis. The conditions can be categorized as mild and severe. Some of the mild conditions associated with the macular edema can be treated with topical steroids.

MARKET DYNAMICS

The non-infectious macular edema treatment market is expected to witness considerable growth due to rise in geriatric population. Moreover, increasing research in drug development for the treatment of non-infectious macular edema is also expected to drive the market growth. However, lack of awareness amongst general populations, especially in emerging countries is estimated to hamper the growth of the global non-infectious macular edema treatment market.

MARKET SCOPE

The "Non-infectious Macular Edema Treatment Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Non-infectious Macular Edema Treatment Market with detailed market segmentation by drug type, route of administration, and distribution channel. The Non-infectious Macular Edema Treatment Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Non-infectious Macular Edema Treatment Market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The non-infectious macular edema treatment market is segmented on the basis of drug type, route of administration, and distribution channel. Based on drug type, the market is segmented as anti-VEGF, corticosteroids, immunosuppressant, biologics, and others. Based on route of administration, the market is segmented as oral, topical, and others. Based on distribution channel, the market is segmented as hospital pharmacies, online pharmacies, and retail pharmacies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Non-infectious Macular Edema Treatment Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Non-infectious Macular Edema Treatment Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Non-infectious Macular Edema Treatment Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Non-infectious Macular Edema Treatment Market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Non-infectious Macular Edema Treatment Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Non-infectious Macular Edema Treatment Market are anticipated to have lucrative growth opportunities in the future with the rising demand for smart hospital beds in the global market. Below mentioned is the list of few companies engaged in the Non-infectious Macular Edema Treatment Market.

The report also includes the profiles of key players in Non-infectious Macular Edema Treatment Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Allergan, Plc.
  •  Amgen, Inc.
  •  Pfizer, Inc.
  •  Novartis AG
  •  F. Hoffman - La Roche Ltd.
  •  AbbVie Inc.
  •  Bayer AG
  •  Valeant Pharmaceuticals Inc.
  •  Alimera Sciences Inc.
  •  Clearside Biomedical, Inc.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Non-infectious Macular Edema Treatment Market - By Drug Type
1.3.2 Non-infectious Macular Edema Treatment Market - By Route of Administration
1.3.3 Non-infectious Macular Edema Treatment Market - By Distribution Channel
1.3.4 Non-infectious Macular Edema Treatment Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. NON-INFECTIOUS MACULAR EDEMA TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. NON-INFECTIOUS MACULAR EDEMA TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NON-INFECTIOUS MACULAR EDEMA TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. NON-INFECTIOUS MACULAR EDEMA TREATMENT - GLOBAL MARKET OVERVIEW
6.2. NON-INFECTIOUS MACULAR EDEMA TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. NON-INFECTIOUS MACULAR EDEMA TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUG TYPE
7.1. OVERVIEW
7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
7.3. ANTI-VEGF
7.3.1. Overview
7.3.2. Anti-VEGF Market Forecast and Analysis
7.4. CORTICOSTEROIDS
7.4.1. Overview
7.4.2. Corticosteroids Market Forecast and Analysis
7.5. IMMUNOSUPPRESSANT
7.5.1. Overview
7.5.2. Immunosuppressant Market Forecast and Analysis
7.6. BIOLOGICS
7.6.1. Overview
7.6.2. Biologics Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. NON-INFECTIOUS MACULAR EDEMA TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. TOPICAL
8.4.1. Overview
8.4.2. Topical Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. NON-INFECTIOUS MACULAR EDEMA TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. ONLINE PHARMACIES
9.4.1. Overview
9.4.2. Online Pharmacies Market Forecast and Analysis
9.5. RETAIL PHARMACIES
9.5.1. Overview
9.5.2. Retail Pharmacies Market Forecast and Analysis
10. NON-INFECTIOUS MACULAR EDEMA TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Non-infectious Macular Edema Treatment Market Overview
10.1.2 North America Non-infectious Macular Edema Treatment Market Forecasts and Analysis
10.1.3 North America Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Drug Type
10.1.4 North America Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Non-infectious Macular Edema Treatment Market
10.1.6.1.1 United States Non-infectious Macular Edema Treatment Market by Drug Type
10.1.6.1.2 United States Non-infectious Macular Edema Treatment Market by Route of Administration
10.1.6.1.3 United States Non-infectious Macular Edema Treatment Market by Distribution Channel
10.1.6.2 Canada Non-infectious Macular Edema Treatment Market
10.1.6.2.1 Canada Non-infectious Macular Edema Treatment Market by Drug Type
10.1.6.2.2 Canada Non-infectious Macular Edema Treatment Market by Route of Administration
10.1.6.2.3 Canada Non-infectious Macular Edema Treatment Market by Distribution Channel
10.1.6.3 Mexico Non-infectious Macular Edema Treatment Market
10.1.6.3.1 Mexico Non-infectious Macular Edema Treatment Market by Drug Type
10.1.6.3.2 Mexico Non-infectious Macular Edema Treatment Market by Route of Administration
10.1.6.3.3 Mexico Non-infectious Macular Edema Treatment Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Non-infectious Macular Edema Treatment Market Overview
10.2.2 Europe Non-infectious Macular Edema Treatment Market Forecasts and Analysis
10.2.3 Europe Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Drug Type
10.2.4 Europe Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Non-infectious Macular Edema Treatment Market
10.2.6.1.1 Germany Non-infectious Macular Edema Treatment Market by Drug Type
10.2.6.1.2 Germany Non-infectious Macular Edema Treatment Market by Route of Administration
10.2.6.1.3 Germany Non-infectious Macular Edema Treatment Market by Distribution Channel
10.2.6.2 France Non-infectious Macular Edema Treatment Market
10.2.6.2.1 France Non-infectious Macular Edema Treatment Market by Drug Type
10.2.6.2.2 France Non-infectious Macular Edema Treatment Market by Route of Administration
10.2.6.2.3 France Non-infectious Macular Edema Treatment Market by Distribution Channel
10.2.6.3 Italy Non-infectious Macular Edema Treatment Market
10.2.6.3.1 Italy Non-infectious Macular Edema Treatment Market by Drug Type
10.2.6.3.2 Italy Non-infectious Macular Edema Treatment Market by Route of Administration
10.2.6.3.3 Italy Non-infectious Macular Edema Treatment Market by Distribution Channel
10.2.6.4 Spain Non-infectious Macular Edema Treatment Market
10.2.6.4.1 Spain Non-infectious Macular Edema Treatment Market by Drug Type
10.2.6.4.2 Spain Non-infectious Macular Edema Treatment Market by Route of Administration
10.2.6.4.3 Spain Non-infectious Macular Edema Treatment Market by Distribution Channel
10.2.6.5 United Kingdom Non-infectious Macular Edema Treatment Market
10.2.6.5.1 United Kingdom Non-infectious Macular Edema Treatment Market by Drug Type
10.2.6.5.2 United Kingdom Non-infectious Macular Edema Treatment Market by Route of Administration
10.2.6.5.3 United Kingdom Non-infectious Macular Edema Treatment Market by Distribution Channel
10.2.6.6 Rest of Europe Non-infectious Macular Edema Treatment Market
10.2.6.6.1 Rest of Europe Non-infectious Macular Edema Treatment Market by Drug Type
10.2.6.6.2 Rest of Europe Non-infectious Macular Edema Treatment Market by Route of Administration
10.2.6.6.3 Rest of Europe Non-infectious Macular Edema Treatment Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Non-infectious Macular Edema Treatment Market Overview
10.3.2 Asia-Pacific Non-infectious Macular Edema Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Drug Type
10.3.4 Asia-Pacific Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Non-infectious Macular Edema Treatment Market
10.3.6.1.1 Australia Non-infectious Macular Edema Treatment Market by Drug Type
10.3.6.1.2 Australia Non-infectious Macular Edema Treatment Market by Route of Administration
10.3.6.1.3 Australia Non-infectious Macular Edema Treatment Market by Distribution Channel
10.3.6.2 China Non-infectious Macular Edema Treatment Market
10.3.6.2.1 China Non-infectious Macular Edema Treatment Market by Drug Type
10.3.6.2.2 China Non-infectious Macular Edema Treatment Market by Route of Administration
10.3.6.2.3 China Non-infectious Macular Edema Treatment Market by Distribution Channel
10.3.6.3 India Non-infectious Macular Edema Treatment Market
10.3.6.3.1 India Non-infectious Macular Edema Treatment Market by Drug Type
10.3.6.3.2 India Non-infectious Macular Edema Treatment Market by Route of Administration
10.3.6.3.3 India Non-infectious Macular Edema Treatment Market by Distribution Channel
10.3.6.4 Japan Non-infectious Macular Edema Treatment Market
10.3.6.4.1 Japan Non-infectious Macular Edema Treatment Market by Drug Type
10.3.6.4.2 Japan Non-infectious Macular Edema Treatment Market by Route of Administration
10.3.6.4.3 Japan Non-infectious Macular Edema Treatment Market by Distribution Channel
10.3.6.5 South Korea Non-infectious Macular Edema Treatment Market
10.3.6.5.1 South Korea Non-infectious Macular Edema Treatment Market by Drug Type
10.3.6.5.2 South Korea Non-infectious Macular Edema Treatment Market by Route of Administration
10.3.6.5.3 South Korea Non-infectious Macular Edema Treatment Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Non-infectious Macular Edema Treatment Market
10.3.6.6.1 Rest of Asia-Pacific Non-infectious Macular Edema Treatment Market by Drug Type
10.3.6.6.2 Rest of Asia-Pacific Non-infectious Macular Edema Treatment Market by Route of Administration
10.3.6.6.3 Rest of Asia-Pacific Non-infectious Macular Edema Treatment Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Non-infectious Macular Edema Treatment Market Overview
10.4.2 Middle East and Africa Non-infectious Macular Edema Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Drug Type
10.4.4 Middle East and Africa Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Non-infectious Macular Edema Treatment Market
10.4.6.1.1 South Africa Non-infectious Macular Edema Treatment Market by Drug Type
10.4.6.1.2 South Africa Non-infectious Macular Edema Treatment Market by Route of Administration
10.4.6.1.3 South Africa Non-infectious Macular Edema Treatment Market by Distribution Channel
10.4.6.2 Saudi Arabia Non-infectious Macular Edema Treatment Market
10.4.6.2.1 Saudi Arabia Non-infectious Macular Edema Treatment Market by Drug Type
10.4.6.2.2 Saudi Arabia Non-infectious Macular Edema Treatment Market by Route of Administration
10.4.6.2.3 Saudi Arabia Non-infectious Macular Edema Treatment Market by Distribution Channel
10.4.6.3 U.A.E Non-infectious Macular Edema Treatment Market
10.4.6.3.1 U.A.E Non-infectious Macular Edema Treatment Market by Drug Type
10.4.6.3.2 U.A.E Non-infectious Macular Edema Treatment Market by Route of Administration
10.4.6.3.3 U.A.E Non-infectious Macular Edema Treatment Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Non-infectious Macular Edema Treatment Market
10.4.6.4.1 Rest of Middle East and Africa Non-infectious Macular Edema Treatment Market by Drug Type
10.4.6.4.2 Rest of Middle East and Africa Non-infectious Macular Edema Treatment Market by Route of Administration
10.4.6.4.3 Rest of Middle East and Africa Non-infectious Macular Edema Treatment Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Non-infectious Macular Edema Treatment Market Overview
10.5.2 South and Central America Non-infectious Macular Edema Treatment Market Forecasts and Analysis
10.5.3 South and Central America Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Drug Type
10.5.4 South and Central America Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Non-infectious Macular Edema Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Non-infectious Macular Edema Treatment Market
10.5.6.1.1 Brazil Non-infectious Macular Edema Treatment Market by Drug Type
10.5.6.1.2 Brazil Non-infectious Macular Edema Treatment Market by Route of Administration
10.5.6.1.3 Brazil Non-infectious Macular Edema Treatment Market by Distribution Channel
10.5.6.2 Argentina Non-infectious Macular Edema Treatment Market
10.5.6.2.1 Argentina Non-infectious Macular Edema Treatment Market by Drug Type
10.5.6.2.2 Argentina Non-infectious Macular Edema Treatment Market by Route of Administration
10.5.6.2.3 Argentina Non-infectious Macular Edema Treatment Market by Distribution Channel
10.5.6.3 Rest of South and Central America Non-infectious Macular Edema Treatment Market
10.5.6.3.1 Rest of South and Central America Non-infectious Macular Edema Treatment Market by Drug Type
10.5.6.3.2 Rest of South and Central America Non-infectious Macular Edema Treatment Market by Route of Administration
10.5.6.3.3 Rest of South and Central America Non-infectious Macular Edema Treatment Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL NON-INFECTIOUS MACULAR EDEMA TREATMENT MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. NON-INFECTIOUS MACULAR EDEMA TREATMENT MARKET, KEY COMPANY PROFILES
13.1. ALLERGAN, PLC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. AMGEN, INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. PFIZER, INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. NOVARTIS AG
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. F. HOFFMAN - LA ROCHE LTD.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. ABBVIE INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. BAYER AG
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. VALEANT PHARMACEUTICALS INC.
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. ALIMERA SCIENCES INC.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. CLEARSIDE BIOMEDICAL, INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Allergan, Plc.
2. Amgen, Inc.
3. Pfizer, Inc.
4. Novartis AG
5. F. Hoffman - La Roche Ltd.
6. AbbVie Inc.
7. Bayer AG
8. Valeant Pharmaceuticals Inc.
9. Alimera Sciences Inc.
10. Clearside Biomedical, Inc.
TIPRE00016867
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking